Authors:
Brandt, CM
Honscha, M
Truong, ND
Holland, R
Hovener, B
Bryskier, A
Lutticken, R
Reinert, RR
Citation: Cm. Brandt et al., Microlide resistance in Streptococcus pyogenes isolates from throat infections in the region of Aachen, Germany (vol 7, pg 165, 2001), MICROB DR R, 7(3), 2001, pp. NIL_6-NIL_6
Authors:
Brandt, CM
Honscha, M
Truong, ND
Holland, R
Hovener, B
Bryskier, A
Lutticken, R
Reinert, RR
Citation: Cm. Brandt et al., Macrolide resistance in Streptococcus pyogenes isolates from throat infections in the region of Aachen, Germany, MICROB DR R, 7(2), 2001, pp. 165-170
Authors:
Lascols, C
Bryskier, A
Soussy, CJ
Tankovic, J
Citation: C. Lascols et al., Effect of pH on the susceptibility of Helicobacter pylori to the ketolide telithromycin (HMR 3647) and clarithromycin, J ANTIMICRO, 48(5), 2001, pp. 738-740
Authors:
Nagai, K
Davies, TA
Ednie, LM
Bryskier, A
Palavecino, E
Jacobs, MR
Appelbaum, PC
Citation: K. Nagai et al., Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S-pyogenes, ANTIM AG CH, 45(11), 2001, pp. 3242-3245
Authors:
Joly-Guillou, ML
Wolff, M
Farinotti, R
Bryskier, A
Carbon, C
Citation: Ml. Joly-guillou et al., In vivo activity of levofloxacin alone or in combination with imipenem or amikacin in a mouse model of Acinetobacter baumannii pneumonia, J ANTIMICRO, 46(5), 2000, pp. 827-830
Authors:
Rastogi, N
Goh, KS
Berchel, M
Bryskier, A
Citation: N. Rastogi et al., Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M-bovis BCG, J ANTIMICRO, 46(4), 2000, pp. 565-570
Authors:
Bemer-Melchior, P
Bryskier, A
Drugeon, HB
Citation: P. Bemer-melchior et al., Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex, J ANTIMICRO, 46(4), 2000, pp. 571-575
Authors:
Bebear, CM
Renaudin, H
Bryskier, A
Bebear, C
Citation: Cm. Bebear et al., Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas, ANTIM AG CH, 44(7), 2000, pp. 1980-1982
Citation: D. Vazifeh et al., Effect of proinflammatory cytokines on the interplay between roxithromycin, HMR 3647, or HMR 3004 and human polymorphonuclear neutrophils, ANTIM AG CH, 44(3), 2000, pp. 511-521
Authors:
Bemer-Melchior, P
Juvin, ME
Tassin, S
Bryskier, A
Schito, GC
Drugeon, HB
Citation: P. Bemer-melchior et al., In vitro activity of the new ketolide telithromycin compared with those ofmacrolides against Streptococcus pyogenes: Influences of resistance mechanisms and methodological factors, ANTIM AG CH, 44(11), 2000, pp. 2999-3002
Authors:
Rastogi, N
Goh, KS
Berchel, M
Bryskier, A
Citation: N. Rastogi et al., In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004compared to those of clarithromycin against slowly growing mycobacteria atpHs 6.8 and 7.4, ANTIM AG CH, 44(10), 2000, pp. 2848-2852
Citation: E. Bergogne-berezin et A. Bryskier, The suppository form of antibiotic administration: pharmacokinetics and clinical application, J ANTIMICRO, 43(2), 1999, pp. 177-185
Authors:
Fernandez-Roblas, R
Calvo, R
Esteban, J
Bryskier, A
Soriano, F
Citation: R. Fernandez-roblas et al., The bactericidal activities of HMR 3004, HMR 3647 and erythromycin againstGram-positive bacilli and development of resistance, J ANTIMICRO, 43(2), 1999, pp. 285-289
Authors:
Soriano, F
Fernandez-Roblas, R
Calvo, R
Garcia-Calvo, G
Pardeiro, M
Bryskier, A
Citation: F. Soriano et al., In-vitro antimicrobial activity of HMR 3004 (RU 64004) against erythromycin A-sensitive and -resistant Corynebacterium spp. isolated from clinical specimens, J ANTIMICRO, 42(5), 1998, pp. 647-649
Authors:
Araujo, FG
Khan, AA
Bryskier, A
Remington, JS
Citation: Fg. Araujo et al., Use of ketolides in combination with other drugs to treat experimental toxoplasmosis, J ANTIMICRO, 42(5), 1998, pp. 665-667